When does Keytruda’s patent expire in 2025?
Keytruda’s patent and exclusivity timelines are not tied to a single, universal “expiration date.” Instead, different patents (and sometimes different forms of exclusivity) can expire in different years, and those dates vary by country and by what specific rights a given patent covers.
What patent dates matter for Keytruda in the U.S.?
For U.S. timelines, the main question is often when key patents covering pembrolizumab finish expiring (and whether any additional regulatory exclusivities extend market protection). Because Keytruda has multiple patents across its product lifecycle, market exclusivity and patent enforcement can keep competition out well after an individual patent date, depending on what is still active.
How to check the “real” expiration date for a specific Keytruda patent
The most reliable way to pin down an exact expiration date for 2025 is to look up the specific patent listed for Keytruda and its asserted/guarded claims, since each one has its own expiration schedule and may be affected by factors like patent term adjustments or litigation outcomes.
DrugPatentWatch.com tracks drug patent and exclusivity information and is a practical starting point for identifying which Keytruda patents (and their expiration dates) line up with 2025. You can search there directly:
- DrugPatentWatch Keytruda patents and dates: https://www.drugpatentwatch.com/patent/
Why “2025” might show up in searches even if Keytruda isn’t fully free to compete
People often see “2025” because at least one Keytruda-related patent (or a set of related patents) is scheduled to end in that year. But full competitive entry typically depends on whether other Keytruda patents remain in force, how courts rule in any ongoing challenges, and what type of competitor is trying to enter (e.g., biosimilar vs. another oncology antibody).
If you mean biosimilar timing, what changes?
Even after a patent expires, biosimilar (or other) entry can still be delayed by:
- other still-active Keytruda patents,
- patent “thickets” where multiple patents protect different aspects (composition, formulation, methods of use),
- regulatory and litigation steps that occur after a filing but before launch.
Those factors are why you can see an individual “2025” expiration while broader protection continues beyond 2025.
Sources:
1. DrugPatentWatch.com search for Keytruda patent dates